受容体型チロシンキナーゼ
(Receptor-Tyrosine Kinase から転送)
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/11/01 14:50 UTC 版)
受容体型チロシンキナーゼ（じゅようたいがたチロシンキナーゼ、英: receptor tyrosine kinase、略称: RTK）は、多くのポリペプチド型成長因子、サイトカイン、ホルモンに対する高親和性の細胞表面受容体である。ヒトゲノムでは90種類のチロシンキナーゼの遺伝子が同定されており、そのうち58種類が受容体型チロシンキナーゼをコードする[1]。受容体型チロシンキナーゼは正常な細胞機能の重要な調節因子であるだけでなく、多くの種類のがんの発生と増悪においても重要な役割を担うことが示されている[2]。受容体型チロシンキナーゼの変異は一連のシグナル伝達カスケードの活性化を引き起こし、タンパク質の発現に多くの影響を与える[3]。
- ^ “The protein tyrosine kinase family of the human genome”. Oncogene 19 (49): 5548–57. (November 2000). doi:10.1038/sj.onc.1203957. PMID 11114734.
- ^ a b c d “Receptor tyrosine kinase signalling as a target for cancer intervention strategies”. Endocrine-Related Cancer 8 (3): 161–73. (September 2001). doi:10.1677/erc.0.0080161. PMID 11566607.
- ^ “Cell signaling by receptor tyrosine kinases”. Cell 141 (7): 1117–34. (June 2010). doi:10.1016/j.cell.2010.06.011. PMC 2914105. PMID 20602996.
- ^ “Protein tyrosine kinase structure and function”. Annual Review of Biochemistry 69: 373–98. (2000). doi:10.1146/annurev.biochem.69.1.373. PMID 10966463.
- ^ Ségaliny, Aude I.; Tellez-Gabriel, Marta; Heymann, Marie-Françoise; Heymann, Dominique (2015). “Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers”. J. Bone Oncol. 4 (1): 1–12. doi:10.1016/j.jbo.2015.01.001. PMC 4620971. PMID 26579483.
- ^ Lodish (2003). Molecular cell biology (5th ed.)
- ^ “Structural analysis of receptor tyrosine kinases”. Progress in Biophysics and Molecular Biology 71 (3–4): 343–58. (1999). doi:10.1016/S0079-6107(98)00047-9. PMID 10354703.
- ^ “Cell signaling by receptor tyrosine kinases”. Cell 141 (7): 1117–34. (June 2010). doi:10.1016/j.cell.2010.06.011. PMC 2914105. PMID 20602996.
- ^ “Protein modules and signalling networks”. Nature 373 (6515): 573–80. (February 1995). Bibcode: 1995Natur.373..573P. doi:10.1038/373573a0. PMID 7531822.
- ^ “The conservation pattern of short linear motifs is highly correlated with the function of interacting protein domains”. BMC Genomics 9: 452. (October 2008). doi:10.1186/1471-2164-9-452. PMC 2576256. PMID 18828911.
- ^ “The EGF receptor family: spearheading a merger of signaling and therapeutics”. Current Opinion in Cell Biology 19 (2): 124–34. (April 2007). doi:10.1016/j.ceb.2007.02.008. PMID 17314037.
- ^ “Fibroblast growth factors”. Genome Biology 2 (3): REVIEWS3005. (2001). doi:10.1186/gb-2001-2-3-reviews3005. PMC 138918. PMID 11276432.
- ^ a b “N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding”. The Journal of Biological Chemistry 281 (37): 27178–89. (September 2006). doi:10.1074/jbc.M601248200. PMID 16829530.
- ^ “Receptors for fibroblast growth factors”. Immunology and Cell Biology 73 (6): 584–9. (December 1995). doi:10.1038/icb.1995.92. PMID 8713482.
- ^ “Identification of a new fibroblast growth factor receptor, FGFR5”. Gene 271 (2): 171–82. (June 2001). doi:10.1016/S0378-1119(01)00518-2. PMID 11418238.
- ^ “The splice variants of vascular endothelial growth factor (VEGF) and their receptors”. Journal of Cell Science 114 (Pt 5): 853–65. (March 2001). PMID 11181169.
- ^ “Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET”. Oncogene 11 (10): 2039–45. (November 1995). PMID 7478523.
- ^ “The GDNF family ligands and receptors - implications for neural development”. Current Opinion in Neurobiology 10 (1): 103–10. (February 2000). doi:10.1016/S0959-4388(99)00048-3. PMID 10679429.
- ^ “GDNF family neurotrophic factor signaling: four masters, one servant?”. Molecular and Cellular Neurosciences 13 (5): 313–25. (May 1999). doi:10.1006/mcne.1999.0754. PMID 10356294.
- ^ “RET tyrosine kinase signaling in development and cancer”. Cytokine & Growth Factor Reviews 16 (4–5): 441–67. (2005). doi:10.1016/j.cytogfr.2005.05.010. PMID 15982921.
- ^ “Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling”. The Journal of Biological Chemistry 288 (11): 7430–7. (March 2013). doi:10.1074/jbc.R112.444158. PMC 3597784. PMID 23335507.
- ^ “Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases”. Trends in Cell Biology 11 (6): 258–66. (June 2001). doi:10.1016/s0962-8924(01)01990-0. PMID 11356362.
- ^ “Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B” (英語). The Journal of Biological Chemistry 278 (2): 739–44. (January 2003). doi:10.1074/jbc.M210194200. PMID 12424235.
- ^ “Complexity of receptor tyrosine kinase signal processing”. Cold Spring Harbor Perspectives in Biology 5 (8): a009043. (August 2013). doi:10.1101/cshperspect.a009043. PMC 3721286. PMID 23906711.
- ^ a b “Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field”. Biomarker Insights 2: 45–58. (February 2007). PMC 2717834. PMID 19662191.
- ^ “Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases”. Proceedings of the National Academy of Sciences of the United States of America 94 (5): 1680–5. (March 1997). Bibcode: 1997PNAS...94.1680F. doi:10.1073/pnas.94.5.1680. PMC 19976. PMID 9050838.
- ^ “Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling”. The Journal of Biological Chemistry 271 (33): 19810–6. (August 1996). doi:10.1074/jbc.271.33.19810. PMID 8702689.
- ^ “CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells”. Immunological Reviews 228 (1): 288–311. (March 2009). doi:10.1111/j.1600-065X.2008.00752.x. PMC 2739744. PMID 19290935.
- ^ “Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor”. Oncogene 20 (37): 5199–209. (August 2001). doi:10.1038/sj.onc.1204555. PMID 11526509.
- ^ “Cell signaling by receptor tyrosine kinases”. Cell 141 (7): 1117–34. (June 2010). doi:10.1016/j.cell.2010.06.011. PMC 2914105. PMID 20602996.
- ^ “Targeting the EGFR signaling pathway in cancer therapy”. Expert Opinion on Therapeutic Targets 16 (1): 15–31. (January 2012). doi:10.1517/14728222.2011.648617. PMC 3291787. PMID 22239438.
- ^ “HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review”. British Journal of Cancer 90 (12): 2344–8. (June 2004). doi:10.1038/sj.bjc.6601881. PMC 2409528. PMID 15150568.
- ^ “Cell signaling by receptor tyrosine kinases”. Cell 141 (7): 1117–34. (June 2010). doi:10.1016/j.cell.2010.06.011. PMC 2914105. PMID 20602996.
[続きの解説]
「受容体型チロシンキナーゼ」の続きの解説一覧
- 1 受容体型チロシンキナーゼとは
- 2 受容体型チロシンキナーゼの概要
- 3 キナーゼ活性
- 4 調節
- 5 薬剤治療
- 6 関連項目
- Receptor-Tyrosine Kinaseのページへのリンク
